Showing all 4 results
Antacid & Anti-Ulcerant Tablets
FreeTechnical & Logistics Specifications
Parameter Specifications & Standards HS Code 3004.90.99 (Medicaments acting on the alimentary tract and metabolism) Pharmacopeia Compliance IP / BP / USP / EP Dosage Formats Enteric-Coated, Delayed-Release, Film-Coated, and Chewable Tablets Export Packaging 10 / 14 / 15 Tablets per Blister packed exclusively in high-barrier Alu-Alu (Cold-Form Foil) or thick PVC/PVDC matrixes to protect against moisture ingress in Zone IVb tropical climates. Shelf-Life Stability Fully validated 36-Month real-time stability metrics Lisinopril Tablet
FreeProduct Composition & Available Portfolio Range
We manufacture Lisinopril in exact, compendial strengths calibrated to support initial introductory titration up to high-potency cardioprotective maintenance blocks.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Lisinopril Anhydrous / Dihydrate USP / BP / IP 5 mg Oral Solid Uncoated Tablet Initial Titration: For low-dose introductory management, pediatric hypertension, or initial combination therapy initiation. Lisinopril Anhydrous / Dihydrate USP / BP / IP 10 mg Oral Solid Uncoated Tablet Core Commercial Volume: Standard international baseline daily dose for mild-to-moderate chronic essential hypertension. Lisinopril Anhydrous / Dihydrate USP / BP / IP 20 mg Oral High-Potency Solid Tablet Advanced Cardioprotection: High-strength configuration calibrated for severe heart failure management and post-infarction survival optimization. Nifedipine Tablet
FreeProduct Composition & Structural Formats
We manufacture Nifedipine across the complete clinical dosage spectrum, utilizing distinct release matrices calibrated for immediate stabilization or sustained, once-daily therapeutic coverage.
Active Ingredient Available Strengths Formulation Matrix Delivery System Primary Clinical Focus Nifedipine IP/BP/USP 10 mg Immediate-Release / Rapid-Onset Film Tablet Acute Titration / Tocolysis: For severe acute hypertension or suppression of premature labor contractions. Nifedipine IP/BP/USP 20 mg Sustained-Release (SR) Retard Matrix Twice-Daily Maintenance: Intermediate control for stable chronic hypertension. Nifedipine IP/BP/USP 30 mg Once-Daily Extended-Release (XR / XL) Matrix First-Line Chronic Care: Continuous 24-hour plasma stabilization for mild-to-moderate hypertension. Nifedipine IP/BP/USP 60 mg Once-Daily Extended-Release (XR / XL) Matrix High-Potency Control: For refractory essential hypertension and severe chronic stable angina pectoris. Pantoprazole Tablets
FreePantoprazole Tablets IP 40 mg
Each Enteric Coated tablet contains
Pantoprazole Sodium IP
Eq. To Pantoprazole 40 mgPenta-20
Pantoprazole Tablets 20 mg
Each Enteric Coated Tablet Contains
Pantoprazole Sodium Sesquihydrate
Eq To Pantoprazole 20 mgPenta – 40
Pantoprazole Tablets 40 mg
Each Entreric Coated tablet contains
Pantoprazole Sodium Sesquihydrate
Eq. To pantoprazole 40 mgUsage: – Heartburn, acid reflux and gastro-esophageal reflux disease
Category: – Antacid & Anti ulcer drugs
Therapeutic category: – Antiulcer, Antacid






